Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02746367 · ClinicalTrials.gov registry record
Bipolar Proteomic Assay Validation Study
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Completed
- Registry status
- 261
- Enrollment target
NCT02746367: Completed study, sponsored by Myriad Genetic Laboratories.
NCT02746367 is a clinical trial that has completed, run by Myriad Genetic Laboratories. The registered enrollment target is 261 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02746367 has completed, sponsored by Myriad Genetic Laboratories.
- COMPLETED
- Registry status
- 261 participants
- Enrollment target
Study Summary
The purpose of this study is to validate a set of signatures, based on a panel of proteomic markers, that discriminate BDI, BDII, and MDD in people seeking treatment for a depressive episode.
Interventions
- OTHER Diagnostic test (LDT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-11-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02746367
The ClinicalTrials.gov registry entry for NCT02746367 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myriad Genetic Laboratories, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Diagnostic test (LDT) is the first listed.
NCT02746367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02746367 about?
NCT02746367 is a clinical study titled "Bipolar Proteomic Assay Validation Study". The purpose of this study is to validate a set of signatures, based on a panel of proteomic markers, that discriminate BDI, BDII, and MDD in people seeking treatment for a depressive episode.
What is the current status of trial NCT02746367?
This trial is currently completed. The enrollment target is 261 participants. The study started on 2016-03. Estimated completion is 2018-11-08.
What interventions are being tested in trial NCT02746367?
The interventions under investigation include: Diagnostic test (LDT) (OTHER).
Who is sponsoring clinical trial NCT02746367?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.